Corbus Pharmaceuticals Updates CRB-701 Clinical Data
Corbus Pharmaceuticals reported updated data from its Phase 1/2 clinical study of CRB-701. The new data demonstrate activity in the second line setting of two solid tumor types that express high levels of Nectin-4 and are primarily driven by human papilloma virus: oropharyngeal squamous cell carcinoma and cervical cancer. These findings will be presented at the upcoming 2026 American Society for Clinical Oncology, ASCO, Annual Meeting being held May 29 - June 2, 2026, in Chicago. Key highlights: Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward; Confirmed ORR of 42.9% observed in 2L oropharyngeal squamous cell carcinoma at 3.6 mg/kg with median DOR of 6.3 months and PFS of 5.6 months; Confirmed ORR of 34.4% observed in 2L cervical cancer at 3.6 mg/kg with median DOR of 8.0 months and PFS of 4.3 months; About 50% of 2L head and neck cancer cases in the U.S. are HPV-driven OPSCC and receive minimal to no benefit from EGFR-targeted therapies; Registrational study of CRB-701 in 2L OPSCC on track to initiate in summer 2026
